CSL (EMEA)
Executive or Senior Director Search & Evaluation Late TA Lead, (Im, CV, or He)
CSL (EMEA), Indiana, Pennsylvania, us, 15705
Overview
CSL's R&D organization is accelerating innovation to deliver greater impact for patients. With a project-led structure and a focus on collaboration, we’re building a future-ready team that thrives in dynamic biotech ecosystems. Joining CSL now means being part of an agile team committed to developing therapies that make a meaningful difference worldwide. The Executive or Senior Director Search & Evaluation Late TA Lead, (Im CV or He) role is located in King of Prussia PA, Waltham MA or Zurich Switzerland and is a hybrid position onsite three days a week.
Position Description Summary
The Executive Director of Search & Evaluation will lead strategic sourcing and evaluation of later-stage external clinical assets in Immunology, Hematology, and Cardiovascular/Renal therapeutic areas. In addition, this role will manage all TA Leads for Early and Late Stage. These leaders will focus on opportunities from Phase 2 through marketed drugs, requiring deep clinical expertise, strong engagement with external KOLs and clinical investigators, and a keen understanding of evolving standards of care. The role is critical to shaping our portfolio through high-impact partnerships and transactions.
Main Responsibilities & Accountability
Lead and manage a team of early and late-stage Search & Evaluation TA Leads.
Develop the strategy and a consistent process for all Search & Evaluation activities.
Serve as the senior S&E leader within the TALT, influencing therapeutic strategy and integrating late-stage external innovation priorities into portfolio planning.
Lead proactive sourcing efforts for Phase 2 to marketed assets, identifying opportunities that align with TA strategy and unmet medical needs.
Co-lead internal meetings (with Early Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations.
Engage extensively with external KOLs, clinical investigators, and networks to validate asset potential, understand trial designs & clinical endpoints, and anticipate competitive dynamics.
Maintain deep awareness of changing standards of care and competitive landscapes to inform sourcing priorities and deal strategy.
Drive cross-functional due diligence for late-stage assets, coordinating clinical, regulatory, commercial, and market access assessments to support governance decisions.
Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution.
Represent the TA externally, leading sourcing activities at specialized conferences and building relationships with pharma, biotech, and clinical communities.
Qualifications & Experience / Requirements
15+ years in biopharma with significant experience in clinical development, external innovation, or business development.
Advanced degree required (MD, PhD, or equivalent).
Deep clinical expertise in Immunology, Hematology, or Cardiovascular/Renal therapeutic areas.
Proven track record of sourcing and closing late-stage deals and engaging with KOLs and clinical networks.
Strong understanding of regulatory pathways, market access, and competitive standards of care.
Experience leading a global team.
About CSL Behring CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and address unmet medical needs and help patients lead full lives. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries.
Our Benefits For more information on CSL benefits visit How CSL Supports Your Well-being | CSL.
You Belong at CSL At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out. By celebrating our differences and creating a culture of curiosity and empathy, we are able to better understand and connect with our patients and donors, foster strong relationships with our stakeholders, and sustain a diverse workforce that will move our company and industry into the future.
To learn more about inclusion and belonging visit our careers page.
Equal Opportunity Employer CSL is an Equal Opportunity Employer. If you are an individual with a disability and need a reasonable accommodation for any part of the application process, please visit our accessibility statement.
#J-18808-Ljbffr
Position Description Summary
The Executive Director of Search & Evaluation will lead strategic sourcing and evaluation of later-stage external clinical assets in Immunology, Hematology, and Cardiovascular/Renal therapeutic areas. In addition, this role will manage all TA Leads for Early and Late Stage. These leaders will focus on opportunities from Phase 2 through marketed drugs, requiring deep clinical expertise, strong engagement with external KOLs and clinical investigators, and a keen understanding of evolving standards of care. The role is critical to shaping our portfolio through high-impact partnerships and transactions.
Main Responsibilities & Accountability
Lead and manage a team of early and late-stage Search & Evaluation TA Leads.
Develop the strategy and a consistent process for all Search & Evaluation activities.
Serve as the senior S&E leader within the TALT, influencing therapeutic strategy and integrating late-stage external innovation priorities into portfolio planning.
Lead proactive sourcing efforts for Phase 2 to marketed assets, identifying opportunities that align with TA strategy and unmet medical needs.
Co-lead internal meetings (with Early Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations.
Engage extensively with external KOLs, clinical investigators, and networks to validate asset potential, understand trial designs & clinical endpoints, and anticipate competitive dynamics.
Maintain deep awareness of changing standards of care and competitive landscapes to inform sourcing priorities and deal strategy.
Drive cross-functional due diligence for late-stage assets, coordinating clinical, regulatory, commercial, and market access assessments to support governance decisions.
Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution.
Represent the TA externally, leading sourcing activities at specialized conferences and building relationships with pharma, biotech, and clinical communities.
Qualifications & Experience / Requirements
15+ years in biopharma with significant experience in clinical development, external innovation, or business development.
Advanced degree required (MD, PhD, or equivalent).
Deep clinical expertise in Immunology, Hematology, or Cardiovascular/Renal therapeutic areas.
Proven track record of sourcing and closing late-stage deals and engaging with KOLs and clinical networks.
Strong understanding of regulatory pathways, market access, and competitive standards of care.
Experience leading a global team.
About CSL Behring CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and address unmet medical needs and help patients lead full lives. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries.
Our Benefits For more information on CSL benefits visit How CSL Supports Your Well-being | CSL.
You Belong at CSL At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out. By celebrating our differences and creating a culture of curiosity and empathy, we are able to better understand and connect with our patients and donors, foster strong relationships with our stakeholders, and sustain a diverse workforce that will move our company and industry into the future.
To learn more about inclusion and belonging visit our careers page.
Equal Opportunity Employer CSL is an Equal Opportunity Employer. If you are an individual with a disability and need a reasonable accommodation for any part of the application process, please visit our accessibility statement.
#J-18808-Ljbffr